Ireland - English - HPRA (Health Products Regulatory Authority)

maco pharma (uk) ltd - sodium chloride ; glucose monohydrate - solution for infusion - %w/v - electrolytes with carbohydrates

Ireland - English - HPRA (Health Products Regulatory Authority)

maco pharma (uk) ltd - metronidazole - solution for infusion - 0.5 %w/v - imidazole derivatives

Malta - English - Medicines Authority

pharmazac, s.a. 31 naousis str., 104 47, athens,, greece - sugammadex - solution for injection - sugammadex 200 mg - all other therapeutic products

Malta - English - Medicines Authority

pharmazac, s.a. 31 naousis str., 104 47, athens,, greece - sugammadex - solution for injection - sugammadex 500 mg - all other therapeutic products

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - milrinone 1.43 mg/ml (as lactate. equivalent to 1mg/ml milrinone) - solution for injection - 1 mg/ml - active: milrinone 1.43 mg/ml (as lactate. equivalent to 1mg/ml milrinone) excipient: glucose monohydrate lactic acid sodium hydroxide water for injection - primacor injection is indicated for the short term intravenous therapy of severe congestive heart failure. the majority of experience with intravenous primacor has been in patients receiving digoxin and diuretics. primacor is also indicated for low output states following cardiac surgery, including weaning from cardio-pulmonary bypass pump.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - milrinone, quantity: 1 mg/ml - injection, solution - excipient ingredients: glucose monohydrate; lactic acid; sodium hydroxide; water for injections - primacor injection is indicated for the short term (48 hours) intravenous therapy of severe congestive heart patients in intensive care and coronary care units not responding to other therapy (e.g. digoxin, diuretics, vasodilators, including ace inhibitors). the majority of experience with intravenous primacor has been in patients receiving digoxin and diuretics. primacor is also indicated for low output states following cardiac surgery, including weaning from cardio-pulmonary bypass pump.

European Union - English - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol - asthma - drugs for obstructive airway diseases, - budesonide/formoterol teva pharma b.v. is indicated in adults 18 years of age and older only.asthmabudesonide/formoterol teva pharma b.v. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists.in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists. 

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gabapentin, quantity: 300 mg - capsule, hard - excipient ingredients: maize starch; lactose; purified talc; titanium dioxide; purified water; iron oxide yellow; gelatin; sodium lauryl sulfate - pharmagabapentin is indicated for the treatment of,? partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs.,? neuropathic pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gabapentin, quantity: 400 mg - capsule, hard - excipient ingredients: maize starch; lactose; purified talc; titanium dioxide; purified water; iron oxide yellow; iron oxide red; gelatin; sodium lauryl sulfate - pharmagabapentin is indicated for the treatment of,? partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs.,? neuropathic pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gabapentin, quantity: 100 mg - capsule, hard - excipient ingredients: lactose; purified talc; maize starch; titanium dioxide; purified water; gelatin; sodium lauryl sulfate - pharmagabapentin is indicated for the treatment of,? partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs.,? neuropathic pain.